Crea sito

Neurology News by Xagena

Neurology – NeurologyOnline.net

Neurology, NeurologyOnline.net, Neurology Xagena, Newsletter Xagena, Neurologia Xagena, Aggiornamento in Medicina, Xagena News, Medicine AZ Guide, Newsletter Neurology, Neurology News, Neurology Newsletter, Parkinson Newsletter, Alzheimer Newsletter, Drugs in Neurology Newsletter, Multiple sclerosis Newsletter, Headache Newsletter, Insomnia Newsletter, Migraine Newsletter 
Alpha-synuclein

Higher levels of alpha-synuclein reverse symptoms in Parkinson …
benefits in ON-time, OFF-time …

Further long-term Safinamide use in these … in motor function …
Cholinesterase inhibitors

Efficacy and adverse effects of cholinesterase inhibitors and …
Acetylsalicylic acid

A randomized trial showed that Aspirin ( Acetylsalicylic acid ) is …
Aubagio

Teriflunomide ( Aubagio ) is a once-daily oral immunomodulator …
Copaxone

Search results for “Copaxone” … Sclerosis, provided evidence …
No clinical benefit of …

The proportion of patients with a … no clinical benefit of …
Dimethyl fumarate

Tecfidera for the treatment of adult patients with relapsing remitting …
Safinamide as add-on to …

Safinamide as add-on to Levodopa in mid to late …
Cocaine

Cocaine addiction: molecular … Cocaine might increase their …

Multiple Sclerosis Updates

Multiple Sclerosis News

Relapsing-remitting multiple sclerosis: Plegridy, a PegInterferon beta-1a, approved in European Union

The European Commission ( EC ) has granted marketing authorization for Plegridy ( Peginterferon beta-1a ) as a treatment for adults with relapsing-remitting multiple sclerosis ( RRMS ), the most common form of multiple sclerosis. Plegridy is dosed … more

Multiple sclerosis: Gilenya reduced relapse rates, new MRI lesion counts, brain volume loss and disability progression in previously-treated patients with high disease activity

New analyses of pooled data from the FREEDOMS and FREEDOMS II trials have shown the consistent efficacy of Gilenya ( Fingolimod ) on four key measures of multiple sclerosis disease activity – reducing relapses, new MRI lesion counts, brain volume … more

Atacicept increases clinical disease activity in relapsing multiple sclerosis

Depletion of B lymphocytes is associated with suppression of inflammatory activity in multiple sclerosis. A study has assessed the safety and efficacy of Atacicept, a recombinant fusion protein that suppresses B-cell function and antibody … more

Current perspectives on chronic cerebrospinal venous insufficiency

Chronic cerebrospinal venous insufficiency ( CCSVI ) was initially defined as a clinical syndrome comprising stenoses of the internal jugular and/or azygos veins, characterized by collateral venous outflows and reduced cerebral blood flow, and was … more